Evidence map›Paper›PMID 27646950›Full record

Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2017

Revised Overall Survival Analysis of a Phase II, Randomized, Double-Blind, Controlled Study of PROSTVAC in Men With Metastatic Castration-Resistant Prostate Cancer.

Philip W Kantoff, James L Gulley, Cesar Pico-Navarro

Registry-linked trialOpen access · greenAbstract readClinical Trial, Phase IILetterRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00078585 (A Phase II Randomized, Double Blind, Controlled Study to Evaluate the Safety and Efficacy of PROSTVAC®-VF/TRICOM™ in Combination With GM-CSF in Patients With Androgen-Independent Adenocarcinoma of the Prostate), which is not on this map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
6.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00078585 phase2completednot on this map

A Phase II Randomized, Double Blind, Controlled Study to Evaluate the Safety and Efficacy of PROSTVAC®-VF/TRICOM™ in Combination With GM-CSF in Patients With Androgen-Independent Adenocarcinoma of the Prostate

TypeinterventionalSponsorBavarian NordicRan2003 to 2009Enrolled120ConditionsProstate CancerArmsPROSTVAC®-VF/TRICOM™
3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 65 citations in OpenAlex.

  1. Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2019
    Trial
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Philip W KantoffPhilip W. Kantoff, Memorial Sloan Kettering Cancer Center, New York, NY; James L. Gulley, National Cancer Institute, Bethesda, MD; and Cesar Pico-Navarro, Bavarian Nordic, Redwood City, CA.
James L GulleyPhilip W. Kantoff, Memorial Sloan Kettering Cancer Center, New York, NY; James L. Gulley, National Cancer Institute, Bethesda, MD; and Cesar Pico-Navarro, Bavarian Nordic, Redwood City, CA.
Cesar Pico-NavarroPhilip W. Kantoff, Memorial Sloan Kettering Cancer Center, New York, NY; James L. Gulley, National Cancer Institute, Bethesda, MD; and Cesar Pico-Navarro, Bavarian Nordic, Redwood City, CA.
Bavarian Nordic (United States) · USNational Cancer Institute · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Elisa de Stanchina · 1985 to 2026
$347.4M
Cancer Therapy Clinical Trials Using Novel Recombinant VaccinesZIABC010666 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI GULLEY, JAMES L. · 2009 to 2025
$22.4M
Intramural NIH HHS Z99 CA999999Intramural NIH HHS ZIA BC010666NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Biological TherapyImmunotherapyCancer VaccinesDisease-Free SurvivalDouble-Blind MethodFollow-Up StudiesGranulocyte-Macrophage Colony-Stimulating FactorHumansMaleProstatic Neoplasms, Castration-ResistantReproducibility of ResultsStatistics as TopicSurvival AnalysisTreatment OutcomeCancer VaccinesGranulocyte-Macrophage Colony-Stimulating FactorPROSTVAC

Identifiers

PMID27646950
PMCPMC6411419
OpenAlexW2522481891

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.